Mustang Bio Reports $1.1 Million Net Loss in Q2 2026, Focuses on Cancer Therapy Development

Mustang Bio, Inc. has reported its financial results for the second quarter of 2026, revealing a net loss of $1.1 million, a 41% increase from the $762,000 loss recorded in the same period of 2025. For the six months ending June 30, 2026, the company reported a net loss of $2.0 million, compared to a loss of $915,000 for the first half of 2025. The increase in losses is attributed to higher operating expenses, which rose to $1.2 million in the second quarter, up from $885,000 in the prior year, driven primarily by increased research and development costs.

In terms of financial position, Mustang Bio's cash and cash equivalents decreased to $15.2 million as of June 30, 2026, down from $17.3 million at the end of 2025. The company has an accumulated deficit of $400.7 million, reflecting its ongoing investment in research and development without any revenue generation from product sales. The total liabilities remained relatively stable at $8.1 million, compared to $8.0 million at the end of 2025.

Strategically, Mustang Bio is focused on advancing its pipeline of cancer therapies, particularly through partnerships with leading research institutions. The company is developing CAR T therapy for solid tumors and has received FDA acceptance for its Investigational New Drug (IND) application for a combination therapy targeting glioblastoma. The company anticipates initiating a clinical trial for this combination therapy, known as MB-109, in late 2026. This development is part of Mustang's broader strategy to leverage its partnerships to bring innovative treatments to market.

Operationally, Mustang Bio has not reported any significant changes in customer counts or user statistics, as it remains in the clinical development stage without approved products. The company continues to rely on third-party contractors for clinical trials and manufacturing, which poses risks related to performance and compliance. Additionally, Mustang Bio is currently not in compliance with Nasdaq's minimum bid price requirement, which could affect its stock listing status if not resolved by October 2026.

Looking ahead, Mustang Bio expects to continue incurring significant operating losses as it develops its product candidates. The company has indicated that it has sufficient cash to fund operations for at least the next twelve months but may need to raise additional capital in the future. The ability to secure funding on acceptable terms remains uncertain, and the company acknowledges the potential for dilution of existing shareholders if additional equity is issued.